Name of Submitter

Institution

Title of Abstract

Adam Weiner, MD

University of California, Los Angeles

Correlating prostate-membrane antigen with molecular pathways in treatment naïve prostate cancer

Adrien Holzgreve, MD, MHBA

Ludwig-Maximilians-University of Munich

Randomized phase 2 trial of flexible and extended dosing of 177Lu-PSMA-617 1 molecular radioligand therapy (FLEX-MRT): Study Protocol

Alireza Ghodsi, MD

University of Washington

Validation of a Nomogram for Overall Survival in Patients Receiving 177Lu-PSMA-617 and Proposed Modification to Incorporate Tumor Volumetric Data

Andrea Farolfi, MD

University of California, Los Angeles
IRCCS Azienda Ospedaliero-Universitaria di Bologna

Differences and common ground in 177Lu-PSMA radioligand therapy practice patterns: International survey of 95 theranostic centers

Angela Castellanos Rieger, MD, MSc

University of California, Los Angeles

PSMA PET prognostic value for outcome of pre-chemotherapy post-ARSI CRPC patients
after treatment: a single center retrospective analysis

Anil Bidkar, PhD

University of California, San Francisco

CD46: A Complementary and Alternative Biomarker to PSMA in Prostate Cancer Theranostics

Anju Wadhwa, PhD

University of California, San Francisco

PSMA-Targeted StarPEG Nanocarrier for Imaging and Therapy of Prostate Cancer

Benjamin Nicaise, MSc

Institut Curie

Radiomics Based Prediction of Non Responders to Stereotactic Body Radiation Therapy (SBRT) in Oligometastatic Prostate Cancer Using 68Ga PSMA 11 PET CT : A Retrospective Multicentric Study

Burcak Yilmaz, MD

Oregon Health & Science University

Using artificial intelligence with PSMA PET/CT to predict biochemical response after Lu-177 PSMA Therapy in Metastatic Castration Resistant Prostate Cancer Patients

Catherine Meyer, PhD

Oregon Health & Science University

Leveraging serial quantitative imaging for treatment response monitoring and dosimetry of 177Lu-PSMA-617 therapy

Catherine Meyer, PhD

Oregon Health & Science University

Tandem isotope therapy with 225Ac- and 177Lu-PSMA-617 in a murine model of prostate cancer

Celeste Winters, PhD, DABR

Oregon Health & Science University

Demystifying NRC Release Criteria for Lu-177 PSMA Therapy Patients

Clayton Smith, MD

University of California, Los Angeles

PSMA PET Guided Salvage Radiotherapy Among Prostate Cancer Patients in the Post-Prostatectomy Setting: A Single Center Post-Hoc Analysis

Dimitrios Priftakis, MD

University College London Hospital

Interpretation performance of PROMISE classification system for indeterminate bone uptake on PSMA PET/CT during prostate cancer staging

Ida Sonni, MD

University of California, Los Angeles

Aggressive prostate cancer features on whole-mount histopathology and quantitative measures on PSMA PET

Ida Sonni, MD

University of California, Los Angeles

PSMA PET/CT and mpMRI discrepancies in prostate cancer detection with whole-mount histopathology gold standard

Jan Heilinger, MD

University of Cologne

Threshold for defining PSMA positivity prior to PSMA directed radioligand therapy: A comparison of [68Ga]Ga PSMA 11 and [18F]F-DCFPyL

John Nikitas, MD

University of California, Los Angeles

Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer

John Nikitas, MD

University of California, Los Angeles

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer

Josef Zahner

Ludwig-Maximilians-University of Munich

Impacts of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing 177Lu-PSMA-617 therapy: Preliminary dosimetry results

Kondapa Naidu Bobba, PhD

University of California, San Francisco

Development of 134Ce-PSMA-617 as a novel theranostic pair for 225Ac radiotherapeutics

Lena Unterrainer, MD

Ludwig-Maximilians-University of Munich
University of California, Los Angeles

Low- and high-volume disease in mHSPC, from CHAARTED to PSMA-PET: an international multicenter retrospective study

Linlin Li, PhD, Hank Kung, PhD

Peking Union Medical College
University of Pennsylvania

First in human study of [ 177 Lu] Lu P17 087 and [ 177 Lu] Lu P17 088 in patients with metastatic castration resistant prostate cancer: Comparison of Biodistribution and Dosimetry with [ 177 Lu]Lu PSMA 617

Ruiyue Zhao, Hank Kung, PhD

Guangzhou Medical University
University of Pennsylvania

First in human study of PSMA targeting agent, [ 18 F]AlF P16 093: Dosimetry and initial evaluation in prostate cancer patients

Loïc Djaileb, MD, PhD

Grenoble Alpes University
University of California, Los Angeles

Pre-surgical 68Ga-PSMA-11 PET for biochemical recurrence risk assessment: a surrogate of Pelvic Lymph Node Dissection? Follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial

Luca Valle, MD

University of California, Los Angeles

Radiographic-Pathologic Concordance in the Workup of Locally Radiorecurrent Prostate Cancer

Mahbod Jafarvand, MD

University of California, Los Angeles

PSMA PET/CT for patients with prostate cancer after focal therapy; a single center retrospective analysis

Mariko Nakayama, MD

University of California, Los Angeles

Detection rate and impact on clinical management for [68Ga]Ga-PSMA-11 PET/CT in patients with very low serum PSA levels: a single-center, retrospective analysis

Masatoshi Hotta, MD

University of California, Los Angeles
National Center for Global Health and Medicine, Tokyo

Kinetics of PSMA PET Signal After Radiotherapy in Prostate Cancer Lesions: A Single Center Retrospective Study

Pan Thin

University of California, Los Angeles

When to Repeat a PSMA PET after a Negative Scan in Patients with Recurrent Prostate Cancer under Observation: A Single-Center Retrospective Study

Reinier Hernandez, PhD

University of Wisconsin-Madison

Development of a long-acng PSMA radioligand for targeted alpha therapy of CRPC

Sungmin Woo, MD, PhD

New York University

Equivocal bone lesions on PSMA PET/CT: How common are they and how often are they metastases? A systematic review and meta-analysis

Surekha Yadav, MD

University of California, San Francisco

Lesion-based Response to PSMA Radioligand Therapy: Impact of Absorbed Dose

Vishnu Murthy

University of California, Los Angeles

Exploring the Generalizability of the Prognostic Value of Machine Learning Models Trained on Mid-
Treatment PSMA PET/CT to End-of-Treatment PSMA PET/CT in mCRPC Patients Treated with 177Lu-
PSMA Radioligand Therapy Using the TRAQinform Profile: A Retrospective, Single-Center Analysis

Vishnu Murthy

University of California, Los Angeles

Efficacy and toxicity of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparison with phase 3 VISION data

Wesley Armstrong

University of California, Los Angeles

Prostate cancer disease volume in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer as assessed by PSMA PET: A single center post-hoc retrospective analysis

Wesley Armstrong

University of California, Los Angeles

Impact of PSMA PET/CT on prostate cancer salvage radiotherapy management: results from the prospective randomized phase 3 trial [PSMA SRT NCT03582774]

Zachary Ells

University of California, Los Angeles

Dosimetry of Lutetium-177 PSMA-targeted radiopharmaceutical therapies for prostate cancer patients: a comparative systematic review and meta-analysis

Zachary Ells

University of California, Los Angeles

99mTc-PSMA-I&S radioguided pelvic lymph node dissection in patients with prostate cancer pelvic lymph node metastasis: preliminary results from a prospective exploratory study